ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.94 USD
+0.01 (0.34%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $2.95 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Cash flow Statements
Fiscal Year End for ADC Therapeutics SA falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -240.05 | -155.80 | -230.03 | -246.29 | -116.48 |
Depreciation/Amortization & Depletion | 3.27 | 2.33 | 2.63 | 2.19 | 1.65 |
Net Change from Assets/Liabilities | 44.27 | -33.01 | -20.28 | 12.36 | -7.88 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 73.83 | 49.69 | 14.30 | 63.01 | 1.14 |
Net Cash From Operating Activities | -118.69 | -136.79 | -233.38 | -168.73 | -121.58 |
Property & Equipment | -3.22 | -0.58 | -3.43 | -0.80 | -0.36 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | -1.93 | -3.24 | -2.03 | -1.89 |
Net Cash from Investing Activities | -3.22 | -2.51 | -6.67 | -2.83 | -2.25 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.77 | 5.91 | 0.78 | 433.21 | 0.04 |
Issuance (Repayment) of Debt | 0.00 | -5.49 | 49.59 | 62.90 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | -1.01 | -0.98 | -1.14 | -1.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 73.10 | 0.00 | 218.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 73.88 | -0.59 | 267.39 | 494.97 | 100.51 |
Effect of Exchange Rate Changes | 0.18 | -0.21 | 0.01 | 0.24 | 0.06 |
Net Change In Cash & Equivalents | -47.84 | -140.10 | 27.35 | 323.64 | -23.26 |
Cash at Beginning of Period | 326.44 | 466.54 | 439.20 | 115.55 | 138.81 |
Cash at End of Period | 278.60 | 326.44 | 466.54 | 439.20 | 115.55 |
Diluted Net EPS | -2.94 | -1.99 | -3.00 | -3.77 | -2.36 |
Fiscal Year End for ADC Therapeutics SA falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -83.15 | -46.61 | -240.05 | -154.35 | -106.54 |
Depreciation/Amortization & Depletion | 1.68 | 0.84 | 3.27 | 2.26 | 1.46 |
Net Change from Assets/Liabilities | -14.74 | -9.92 | 44.27 | 34.09 | 33.87 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 19.27 | 11.59 | 73.83 | 32.39 | 19.62 |
Net Cash From Operating Activities | -76.94 | -44.10 | -118.69 | -85.61 | -51.60 |
Property & Equipment | -0.56 | -0.53 | -3.22 | -2.87 | -2.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 |
Net Cash from Investing Activities | -0.56 | -0.53 | -3.22 | -2.69 | -2.03 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 61.81 | 0.36 | 0.77 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -0.87 | -0.46 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 37.25 | 0.00 | 73.10 | 73.10 | 75.00 |
Net Cash from Financing Activities | 99.05 | 0.36 | 73.88 | 72.24 | 74.54 |
Effect of Exchange Rate Changes | -0.03 | -0.04 | 0.18 | 0.03 | 0.15 |
Net Change In Cash & Equivalents | 21.52 | -44.31 | -47.84 | -16.03 | 21.07 |
Cash at Beginning of Period | 278.60 | 278.60 | 326.44 | 326.44 | 326.44 |
Cash at End of Period | 300.12 | 234.29 | 278.60 | 310.41 | 347.51 |
Diluted Net EPS | -0.38 | -0.56 | -1.04 | -0.58 | -0.58 |